Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Statins for primary prevention: what is the regulator's role?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Seeing is believing – the problem of blinding in psychological research

    Research output: Contribution to journalLetter

  2. Should antidepressants be used for major depressive disorder?

    Research output: Contribution to journalReviewpeer-review

  3. Assessing assumptions for statistical analyses in randomised clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Presentation of benefits and harms of antidepressants on websites: A cross-sectional study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

Globally, drug regulators have approved statins for the prevention of cardiovascular disease (CVD), although their use in primary prevention has been controversial. A highly publicised debate has ensued over whether the benefits outweigh the harms. Drug regulators, which are legally required to make independent judgements on drug approvals, have remained silent during the debate. Our aim was to navigate the decision-making processes of European drug regulators and ultimately request the data upon which statins were approved. Our findings revealed a system of fragmented regulation in which many countries licensed statins but did not analyse the data themselves. There is no easily accessible archive containing information about the licensing approval of statins or a central location for holding the trial data. This is an unsustainable model and serves neither the general public, nor researchers.

Original languageEnglish
JournalBMJ Evidence-Based Medicine
Publication statusPublished - 26 Feb 2020

    Research areas

  • clinical trials, coronary heart disease, epidemiology, health policy, ischaemic heart disease

ID: 59639439